RhumbLine Advisers’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

RhumbLine Advisers’s Portfolio VTAE Stock Details VTAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-24,424	Closed	-$511K	–	2893
2016 Q3	$511K	Buy	24,424 +1,210	+5%	+$13.9K	﹤0.01%	2191
2016 Q2	$250K	Buy	23,214 +10,378	+81%	+$88.8K	﹤0.01%	2631
2016 Q1	$85K	Buy	12,836 +100	+0.8%	+$909	﹤0.01%	2921
2015 Q4	$231K	Buy	12,736 +1,855	+17%	+$25.5K	﹤0.01%	2721
2015 Q3	$120K	Buy	10,881 +596	+6%	+$6.33K	﹤0.01%	2918
2015 Q2	$148K	Buy	+10,285	New	+$140K	﹤0.01%	2961

RhumbLine Advisers's VTAE Position: Q4 2016 in Review

RhumbLine Advisers sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2016, closing a stake of 24,424 shares — an estimated $511K sold.

RhumbLine Advisers first reported a position in VTAE in Q2 2015 and held it in 6 quarters. The position peaked at $511K in Q3 2016. 0 funds tracked by Wall St. Rank hold VTAE as of Q4 2016.

RhumbLine Advisers reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2016 after selling out during the quarter.
RhumbLine Advisers sold 24,424 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2016, an estimated $511K.
RhumbLine Advisers first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q2 2015 and held it in 6 quarters.
RhumbLine Advisers's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $511K in Q3 2016.
0 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2016.

Based on RhumbLine Advisers's 13F filing for Q4 2016, filed 27 Jan 2017.